Arcus Biosciences raises $269.7 million from share sale

Arcus Biosciences (RCUS) completed its initial public offering (IPO) and share issuance process, securing $269.7 million in net proceeds, through a consortium led by Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC.

How much did Arcus Biosciences raise from the share sale?

Operating in the healthcare sector, the company, under an agreement signed with brokerages on October 21, 2026, offered at an initial public offering price of $17.50 per share 14,285,715 common shares for sale. Under the agreement, the consortium was granted an option to purchase 2,142,857 additional shares, exercisable for 30 days. The transaction, in which brokerages purchased the shares at a price of $16.45 and exercised their overallotment option in full, closed on October 23, 2026, with the issuance of a total of 16,428,572 shares. After deducting brokerage commissions and estimated offering expenses, approximately $269.7 million in net proceeds was transferred to the company.

How did the stock price react to the share issuance?

Following the conclusion of the share offering, selling pressure was observed in the stock market. Arcus Biosciences shares lost 4.24% on a daily basis, falling to the $18.54 level. During the session in which daily trading volume reached 5,925,215 shares, the stock price retreated to its 52-week low within the range between the $31.57 peak and $18.54 low recorded over the past 1 year.

This content is for information purposes only and does not constitute investment advice.